WASHINGTON, Sept. 22—The Food and Drug Administration (FDA) on Monday approved leucovorin, a folate-based drug, for use in treating certain symptoms associated with autism spectrum disorder (ASD). The decision marks a significant expansion in therapeutic options for children and adolescents facing communication and behavioral challenges. https://healthcare360magazine.com/fda-approves-leucovorin-for-folic-acid/